Vaccines – and allowable remedies for alleged vaccine injuries – are currently the subject of national discussion and considerable misinformation. This session begins with an overview of the basics of vaccine product liability, explaining the 1986 Vaccine Act, civil claims the Vaccine Act allows and prohibits, and the impact of the National Vaccine Injury Compensation Program on product liability. The session then takes a deep dive into both vaccine-related federal multidistrict litigation and examines the defenses vaccine manufacturers have asserted in such litigation. The session concludes with a discussion of the PREP Act and how that statute largely precluded product liability litigation against manufacturers of vaccines and other COVID-19-related treatments during and after the recent pandemic.

This is Part 6 of a eleven-part series. Part 1, The New EU Product Liability Directive: A Game-Changer for Biopharma, Medtech, and Digital Health Companies, is taking place on November 3, 2025, Part 2, Life Sciences Early-Stage Dealmaking: Trends and Diligence Strategy, is taking place on November 3, 2025, Part 3, Navigating the Evolving Frontier of Women’s Health and Fertility Treatments, is taking place on November 4, 2025, Part 4, From Pharma to Produce: California’s Evolving Tort Terrain, is taking place on November 4, Part 5, AI and Life Sciences: A Collision Course, is taking place on November 4, Part 7, A World Without Government Pricing Programs, is taking place on November 5, Part 8, AI and Ethics: Navigating and Challenging Improper Use in Legal Proceedings, is taking place on November 6, Part 9, Hot Topics in Fraud and Abuse for Medical Device Manufacturers, is taking place on November 6, Part 10, Toxic Tort Litigation in the Life Sciences and Consumer Health Industry: Key Cases and Emerging Trends, is taking place on November 7, Part 11, Something New Under the Sun? Novel Preemption Topics, is taking place on November 7.

CLE Information: This webinar is presumptively approved for 1.0 CLE credit in California, Connecticut, Illinois, New Jersey, New York, Pennsylvania, Texas and West Virginia. Applications for CLE credit will be filed in Colorado, Delaware, Florida, Georgia, Ohio, and Virginia. Attendees who are licensed in other jurisdictions will receive a uniform certificate of attendance but Reed Smith only provides credit for the states listed. Please allow 4-6 weeks after the program to receive a certificate of attendance.